Erika P. Hamilton, MD, discusses the role of T-DXd in HER2+ and HER2-low breast cancer, the evolution of CDK4/6 inhibitors in HR+ disease, and how genetic testing supports precision medicine research. @ErikaHamilton9 @SarahCannonDocs #bcsm #OncLiveIPC https://t.co/KYnlhERuBx (@OncLive)

Sacituzumab Govitecan Wins Approval in Europe for Pretreated HR+/HER2– Metastatic Breast Cancer @JavierCortesMD @EU_Commission #bcsm https://t.co/3R7Nhoz78m (@OncLive)

Hey #MedTwitter what’s your take for 3rd line treatment in HER2 3+ gallbladder #cancer currently achieving stable disease under FOLFIRI? @DrAngelaLamarca @ArndtVogel @SaborowskiAnna @JavleMilind @pashtoonkasi @MPishvaian @SebLange #PrecisionMedicine @OncoAlert 🚨 (@BenWestphalen)

Both T-DXd and SG are approved for patients with HER2-low TNBC. But which one has the strongest data in support? - @PTarantinoMD #Cancer #OncoDaily #Oncology #PaoloTarantino #research https://t.co/KCAx079Xbc (@oncodaily)

🎥@ErikaHamilton9(@SarahCannonDocs) shares promising results from a Phase II trial of patritumab deruxtecan in metastatic breast cancer. HER3-DXd shows clinical activity and good tolerability: ➡️https://t.co/mq7yPFixUQ⬅️ #ASCO23 #BreastCancer #BCSM #ImmunoOnc (@VJOncology)

Enhertu improves survival endpoints in HER2-positive solid tumour trial, say @AstraZeneca and Daiichi Sankyo, raising hopes of 'tumour-agnostic' label. #oncology https://t.co/YHbNvWQMUe (@pharmaphorum)

Findings from phase 2 DAISY trial on T-DXd for #BreastCancer treatment demonstrated an ORR of 70.6% in HER2-overexpressing, 37.5% in HER2-low, and 29.7% in HER2 non-expressing tumors 📈 Read the #OpenAccess study in @NatureMedicine by @FerMosele, @FAndreMD and colleagues ➡️… https://t.co/k8JzPACWkv (@OncoViews)

But.. this line, “Although T-DXd provides some clinical benefit in patients with HER2-overexpressing and HER2-low mBC, most of them will ultimately experience disease progression and die.” We need to change this outcome! #bcsm #metastaticbreastcancer #StageIVNeedsMore 😣 (@JaniceTNBCmets)

Both T-DXd and SG are approved for patients with HER2-low TNBC. But which one has the strongest data in support? Which one should be utilized first? Find the answer in our latest letter to the editor, now published on @Annals_Oncology. @curijoey @stolaney1 https://t.co/KqE0aC8FcL (@PTarantinoMD)

Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial. https://t.co/9ljWfZPHk0 @NatureMedicine @EdiBrogi @rovingatuscap @fcschmitt @TheISBP @LuisBlancoJrMD @PTarantinoMD (@HannahYWen)

Trastuzumab deruxtecan exhibits the highest objective response rate in patients with HER2+ metastatic #BreastCancer, but clinical activity is also observed in patients with HER2- or non-expressing tumors @fermosele @FAndreMD @GustaveRoussy #BCSM https://t.co/xciHmNO1wQ (@NatureMedicine)

@AlastairGreyst2 My mum's scan results are back after having to PAY £9K every 3 weeks for ENHERTU for her lung cancer and it's WORKING. Why is this drug not available for all with the HER2? Can you help us push @NICEComms to fast-track this for more people? (@elliely39073921)

Congrats to @Vsalvestrini @kim_kyubo @Icro_Meattini & colleagues for this important work Trastuzumab Emtansine (T-DM1; Kadcyla) Trastuzumab Deruxtecan (T-DXd; Enhertu) DESTINY-Breast03 HER2+ Metastatic signif benefit T-DXd vs. T-DM1 (@PDBrownOnc)

Last #ACSCancerChat question @drfrankiejs @tompowles1 & Dr. Young 🙏 What promising results have we seen with antibody drug conjugates🧪in the treatment of urothelial cancer, specifically enfortumab vedotin and sacituzumab govitecan❓ @OncoAlert 🚨 @VivekSubbiah @WalterStadler5 (@weoncologists)

Enfortumab vedotin and sacituzumab govitecan, two antibody drug conjugates (ADCs), have shown promising results in treating urothelial cancer. They have exhibited significant objective response rates and durable responses, particularly in patients who have previously received… https://t.co/gwK2m0W2M9 (@nataliagandur)

@PBarataMD, MSc, of @TulaneMedicine discussed when to use sacituzumab govitecan for patients with metastatic urothelial cancer. READ MORE: https://t.co/TLQ5Ynezhg (@TargetedOnc)

.@EJonasch, of @MDAndersonNews, shares a phase 1/2 study evaluating PRO1160, a CD70-directed ADC in advanced solid tumors and hematologic malignancies #KCRS23 @kidneycan (@OncLive)

Dr. @EJonasch presented the phase 1/2 trial in progress with a new compound PRO1160 anti-CD70 antibody drug conjugate in solid tumors including RCC. #KCRS23 (@FabioSchutz78)

Not looking: 1A Sacituzumab govitecan = Trop2, br ca 2D Tebentafusp = Gp100, uveal melanoma (w/ HLA serotype selection) 3C Mirvetuximab sorvtansine-gyn = Folate receptor alph ov ca (Guess: gyn = ov ca?) 4B Enfortumab vedotin-ejfv = Nectin-4 bladder/urinary tract ca These are fun (@CDebyaniPhD)

9/15 #TumorBoardTuesday #BCSM 👨🏽‍🔬Other ADCs target Trop2 & are under study. 🥔 Datopotamab deruxtecan (Dato-DXd): targets Trop2 but different linker & payload (also topo-1 inh/same as T-DXd!) 🥔 Similar to SG, no Trop2 testing given ⬆️⬆️ in breast cancer https://t.co/ZWEmXA6pQw (@ArielleMedford)

3/15 #TumorBoardTuesday #BCSM 👨🏽‍🏫Mini tweetorial 1 👩🏼‍🏫 📌Sacituzumab govitecan (SG) = antibody drug conjugate (ADC) 🔹ADCs deliver high levels 💪🏾 of chemo to cells with target 🎯 antigen 🔹SG targets Trop2 (cell signaling protein ⬆️ in many solid tumors) (@ArielleMedford)

4/15 #TumorBoardTuesday #BreastCancer 👨🏽‍🏫Mini tweetorial 2👩🏼‍🏫 📌Sacituzumab govitecan (SG) 🔹approved by the @US_FDA for >2L in metastatic TNBC in 2020 based on landmark ASCENT trial ‼️‼️Approval does 🙅🏼‍♀️ NOT require testing for Trop2‼️‼️ 📚#SaraHurvitz https://t.co/J2nIIy2oeg (@ArielleMedford)

5/15 #TumorBoardTuesday 👨🏽‍🏫Mini tweetorial 3👩🏼‍🏫 📌Sacituzumab govitecan (SG) 🔹first ADC approved for use in TNBC! 🫧2022: ADC T-DXd approved for HER2-low BC, including TNBC ⚠️Currently, SG approved ONLY in metastatic BC 👨🏽‍🔬Ongoing studies evaluating in localized TNBC (NeoSTAR🌟) (@ArielleMedford)

Sacituzumab govitecan demonstrated an overall survival benefit vs physician's choice of treatment in pts w/ pretreated, endocrine-resistant, HR+/HER2– metastatic breast cancer. @stolaney1 @DanaFarber #ASCO23 #bcsm https://t.co/FXPBfKcAC4 (@OncLive)

Antibody drug conjugates, including enfortumab vedotin and sacituzumab govitecan, have continued to show activity in urothelial cancer with promising clinical outcomes. 🔗 https://t.co/WWL08K5gL0 @drfrankiejs @tompowles1 @ChrisSweens1 (@JournalCancer)

Thanks for your feedback! That makes sense. It would be nice to have more options for lung cancer patients, even if this might not be as exciting as Enhertu was for breast cancer. I wonder if certain subgroups fare better, such as oncogene addicted? Wait and see I guess! (@Hilary_Marie_37)

The EMA's Committee for Medicinal Products for Human Use has adopted a positive opinion regarding sacituzumab govitecan monotherapy in select patients with unresectable or metastatic HR–positive, HER2-negative breast cancer. @JavierCortesMD #bcsm https://t.co/jU6u7chlOD (@OncLive)

Trastuzumab deruxtecan in HER2+ GC or GEJ cancer with progression on or after a trastuzumab in the USA & Europe @TheLancetOncol https://t.co/kJEgnmzYdn 🔎DESTINY-02, 79 pts 👉ORR 42%, DoR 8.1, mPFS 5.6, mOS 12.1 mo 👉Clinical activity, DESTINY-Gastric04 waited @myESMO @OncoAlert https://t.co/hLm9rlUdoF (@ArndtVogel)

Sacituzumab govitecan demonstrated an overall survival benefit vs physician's choice of treatment in pts w/ pretreated, endocrine-resistant, HR+/HER2– metastatic breast cancer. @stolaney1 @DanaFarber #ASCO23 #bcsm https://t.co/iqEOwrj4W5 (@OncLive)

Intermittent or continuous FOLFIRI/PANI for 1st line RAS/BRAF WT mCRC: update of survival/toxicity & preliminary results of GA from IMPROVE @ #WCGIC2023 👉Stop & go seems feasible, less toxicity 👉Resistente mechanisms not yet resolved @WCGIC @myESMO @OncoAlert (@ArndtVogel)

Intermittent or continuous FOLFIRI/PANI for 1st line RAS/BRAF WT mCRC: update of survival/toxicity & preliminary results of GA from IMPROVE @ #WCGIC2023 👉Stop & go seems feasible, less toxicity 👉Resistente mechanisms not yet resolved @WCGIC @myESMO @OncoAlert (@ArndtVogel)

Elizabeth A. Mittendorf, MD, PhD, discussed the TROPiCS-02 trial, which evaluated sacituzumab govitecan in HR–positive, HER2-negative breast cancer. #bcsm | @EMittendorfMD @DanaFarber https://t.co/KFZ6dleKn1 (@TargetedOnc)

Single-agent sacituzumab govitecan has received a positive opinion from @EMA_News regarding its use in unresectable or metastatic HR–positive, HER2-negative breast cancer based on data from the phase 3 TROPiCS-02 study. @JavierCortesMD #bcsm https://t.co/urqbkNoe0v (@OncLive)

👍#Flashback @JCO_ASCO @ASCO #CRCsm Almost 20 years ago, these 2 trials defined the tx of #mCRC & have stood the test of time to this day! 📌 N971 - Goldberg et al ➡️ established FOLFOX in 🇺🇸 🇨🇦 📌 Tournigand sequencing study ➡️ established the use of FOLFOX/FOLFIRI 🙏 to… https://t.co/NRaxayz0f4 (@GillSharlene)

👍#Flashback @JCO_ASCO @ASCO #CRCsm Almost 20 years ago, these 2 trials defined the tx of #mCRC & have stood the test of time to this day! 📌 N971 - Goldberg et al ➡️ established FOLFOX in 🇺🇸 🇨🇦 📌 Tournigand sequencing study ➡️ established the use of FOLFOX/FOLFIRI 🙏 to… https://t.co/Jf1E0ttxRA (@GillSharlene)

We are continuing to highlight notable research presented at #ASCO23! Hear @ErikaHamilton9 of @SarahCannonDocs preview findings with HER3-DXd in breast cancer, and check out our site for more insights! @ASCO #bcsm https://t.co/PTMk1yC82M (@OncLive)

This SCLC session is too much fun... despite what he implies in this intro slide @teekayowo delivers an excellent review of lubrinectedin vs topotecan in the elderly. "I don't have SCLC, but if I did, topotecan would not be my first choice!" - Dr. Paul Bunn #DAVAHawaiiLung https://t.co/mK0i1Ni28E (@KE_Gallaway)

Presenting our interim analysis of the US experience in second-line nanoliposomal irinotecan/5-FU/leucovorin in advanced #biliarycancer #WCGIC2023 #Barcelona @WCGIC @myESMO @RueschCenter @anita_turk @RuthHe12 @mnoel3232 @marshalj23 @DrKatePedersen @SitemanCenter (@benweinbergmd)

Compared with physician’s choice treatment, trastuzumab deruxtecan shows a favorable benefit-risk profile in patients with HER2+ metastatic #breastcancer https://t.co/7WsvKf7GIn #fondazionebonadonna #oncology #CancerResearch @CarmenCriscit @BianchiniGP @mauricallari (@FondazioneBona1)

My mom is currently fighting mTNBC. She was previously on Trodelvy and most recently Eribulin. Her Oncologist stopped treatment this past week. Are their any other options for her that you could recommend we maybe explore? (@BladeRunnerOO8)

📽️ New #JCOOP video abstract now available for an article on detecting and managing T-DXd–related interstitial lung disease by @PTarantinoMD & @stolaney1 👉 https://t.co/eGtUFgBD8T #lcsm (@JCOOP_ASCO)

Thanks to @NCCN grant. Phase II Trial of Trifluridine/Tipiracil Plus Irinotecan in Patients with Advanced, Refractory #biliarytractcancer https://t.co/k1YTVB1GO0 @MayoCancerCare @UHhospitals @MiteshBorad @doctorC369 @NCCN @TaihoOncology (@Amitmahipal79)